The Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne bunyavirus that causes high mortality in humans. This enveloped virus harbors two surface glycoproteins (GP), Gn and Gc, that are released by processing of a glycoprotein precursor complex whose maturation takes place in the ER and is completed through the secretion pathway. Here, we characterized the trafficking network exploited by CCHFV GPs during viral assembly, envelopment, and/or egress. We identified membrane trafficking motifs in the cytoplasmic domains (CD) of CCHFV GPs and addressed how they impact these late stages of the viral life cycle using infection and biochemical assays, and confocal microscopy in virus-producing cells. We found that several of the identified CD motifs modulate GP transport through the retrograde trafficking network, impacting envelopment and secretion of infectious particles. Finally, we identified PACS-2 as a crucial host factor contributing to CCHFV GPs trafficking required for assembly and release of viral particles.
The Crimean-Congo Haemorrhagic Fever Virus (CCHFV), a tri-segmented negative-strand virus that belongs to the Orthonairovirus genus, is highly pathogenic in humans but not in other host species. Following infection in humans, CCHFV disseminates widely but replicates most strongly in hepatocytes, indicating a preferential liver tropism. As hepatocytes are the primary site for production and secretion of lipids, here we sought to characterize the interplay between CCHFV and lipoprotein metabolism in hepatocytes. First, we found that CCHFV particles display a heterogeneous profile of density, suggesting various virion compositions. Next, we showed that several lipoprotein components are associated with viral particles. Additionally, we found that pharmacological inhibition or down-regulation of the host factors involved in lipoprotein biogenesis and lipid metabolism could impair CCHFV infection. Our results, therefore, by revealing a close interplay between liver lipid metabolism and CCHFV, highlight the potential of repurposing existing lipid-modulating drugs and allow designing new interventions to curb CCHFV infections.